TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06743334

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2)
Description: 1. 12 years or older~   * Primary series: 2 doses, 30 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot~2. 5 to 11 years of age~   * Primary series: 2 doses, 10 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot~3. 6 months to 4 years of age~   * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2)
Description: 1. 12 years or older~   * Primary series: 2 doses, 30 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot~2. 5 to 11 years of age~   * Primary series: 2 doses, 10 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot~3. 6 months to 4 years of age~   * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2)
Description: 1. 12 years or older~   * Primary series: 2 doses, 30 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot~2. 5 to 11 years of age~   * Primary series: 2 doses, 10 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot~3. 6 months to 4 years of age~   * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
Description: 1. 12 years or older~- Single booster dose, 15/15 μg, administered after ≥3 months after primary series

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
Description: 1. 12 years or older~- Single booster dose, 15/15 μg, administered after ≥3 months after primary series

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
Description: 1. 12 years or older~- Single booster dose, 15/15 μg, administered after ≥3 months after primary series

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
Description: 1. 12 years or older~- Single booster dose, 15/15 μg administered after ≥3 months after primary series

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
Description: 1. 12 years or older~- Single booster dose, 15/15 μg administered after ≥3 months after primary series

Intervention type: BIOLOGICAL
Intervention: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
Description: 1. 12 years or older~- Single booster dose, 15/15 μg administered after ≥3 months after primary series
Study: NCT06743269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Resistance Inspiratory Muscle Strength Training
Description: Performs inspiratory maneuvers at 55% maximal inspiratory pressure (PIMAX) during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3-6.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Resistance Inspiratory Muscle Strength Training
Description: Performs inspiratory maneuvers at 15% maximal inspiratory pressure (PIMAX) for all 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWERbreathe K3 device
Description: Inspiratory muscle training device
Study: NCT05922735

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox
Study: NCT04903509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237
Study: NCT06743269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POWERbreathe K3 device
Description: Inspiratory muscle training device
Study: NCT06742684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI with following SSO2 Therapy
Description: SSO2 Therapy
Study: NCT06742593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT027 cells suspension
Description: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Study: NCT04903509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda®
Description: Saxenda®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saxenda®
Description: Saxenda®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol-ratiopharm®
Description: Paracetamol-ratiopharm®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol-ratiopharm®
Description: Paracetamol-ratiopharm®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol-ratiopharm®
Description: Paracetamol-ratiopharm®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol-ratiopharm®
Description: Paracetamol-ratiopharm®
Study: NCT05186532

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dry Heat Application
Description: 50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moist Heat Application
Description: included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
Study: NCT06481189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-086
Description: The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ilaris®
Description: The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.
Study: NCT06388369

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Description: 2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [177Lu]Lu-PSMA-617
Description: 2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
Study: NCT05837260

Intervention type: OTHER
Intervention: Sample collection only
Description: Sample collection only

Intervention type: OTHER
Intervention: Sample collection only
Description: Sample collection only

Intervention type: OTHER
Intervention: Sample collection only
Description: Sample collection only

Intervention type: OTHER
Intervention: Sample collection only
Description: Sample collection only
Study: NCT05753111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA
Description: PEA supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Maltodextrin supplementation
Study: NCT05056480

Intervention type: OTHER
Intervention: Surveys
Description: Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.

Intervention type: OTHER
Intervention: Surveys
Description: Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.
Study: NCT06070129

Intervention type: PROCEDURE
Intervention: surgical pulmonary embolectomy
Description: open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus

Intervention type: PROCEDURE
Intervention: surgical pulmonary embolectomy
Description: open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
Study: NCT05418361

Intervention type: DRUG
Intervention: ACE inhibitor ,angiotensin receptor blockers
Description: patients taking ACEI or ARBs with cardiovascular disease

Intervention type: DRUG
Intervention: ACE inhibitor ,angiotensin receptor blockers
Description: patients taking ACEI or ARBs with cardiovascular disease
Study: NCT05413447

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Digital consult
Description: Consultations will be prepared digitally using the Mychart patient portal, an elearning and questionnaires. The consultation takes place via Teams.
Study: NCT04777084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
Study: NCT05590039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyEllevate Procedure
Description: The defined study area will be identified and may be marked with a surgical marker.~A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline.
Study: NCT05955573

Intervention type: DIAGNOSTIC_TEST
Intervention: xray
Description: radiological description
Study: NCT06478628

Intervention type: BEHAVIORAL
Intervention: Inpatient rehabilitation
Description: Inpatient multimodal rehabilitation in specialist health care

Intervention type: BEHAVIORAL
Intervention: Inpatient rehabilitation
Description: Inpatient multimodal rehabilitation in specialist health care

Intervention type: BEHAVIORAL
Intervention: Inpatient rehabilitation
Description: Inpatient multimodal rehabilitation in specialist health care

Intervention type: BEHAVIORAL
Intervention: Outpatient day rehabilitation
Description: Multimodal rehabilitation in specialist health care with program lasting whole work days

Intervention type: BEHAVIORAL
Intervention: Outpatient day rehabilitation
Description: Multimodal rehabilitation in specialist health care with program lasting whole work days

Intervention type: BEHAVIORAL
Intervention: Outpatient day rehabilitation
Description: Multimodal rehabilitation in specialist health care with program lasting whole work days
Study: NCT05117489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 150 mg
Description: Miricorilant 150 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 150 mg
Description: Miricorilant 150 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 100 mg
Description: Miricorilant 100 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 100 mg
Description: Miricorilant 100 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 100 mg
Description: Miricorilant 100 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 100 mg
Description: Miricorilant 100 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 50 mg
Description: Miricorilant 50 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 50 mg
Description: Miricorilant 50 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 50 mg
Description: Miricorilant 50 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 50 mg
Description: Miricorilant 50 mg for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 10 mg
Description: Miricorilant 10 mg for oral dosing.
Study: NCT06463860

Intervention type: DEVICE
Intervention: DermDx
Description: DermDx is a computer-aided diagnosis (CADx) software product that uses an AI-based algorithm to evaluate non-invasively captured images of skin lesions obtained from any commercially available dermoscopes. DermDx uses state-of-the-art deep neural network models that have been trained on a large database of dermoscopy images. DermDx analyzes the image of a new skin lesion and provides an output.
Study: NCT05806593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Back pilot
Description: A health-promoting program, targeting physical activity behavior, with a person-centred approach led by a physiotherapist digitally during 12 weeks.
Study: NCT05354544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived SVF
Description: A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
Study: NCT06483893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided thyroid cartilage plane block (group TCPB)
Description: Participants in the (group TCPB) will receive US-guided thyroid cartilage plane block. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided traditional superior laryngeal nerve block (group traditional SLNB)
Description: Participants in the (group traditional SLNB) will receive US-guided traditional superior laryngeal nerve block. Traditional Superior Laryngeal Nerve Block is performed using the thyrohyoid muscle and thyrohyoid membrane as an anatomical landmark. The thyroid cartilage and the greater horn of hyoid bone are hyperechoic signals on sonography. 3ml of 2% lidocaine is injected above the thyrohyoid membrane next to the superior laryngeal artery between two hyperechoic structures. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
Study: NCT06249477

Intervention type: DEVICE
Group type: OTHER
Intervention: Wrist activity tracker and scale
Description: Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist activity tracker and scale
Description: Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Coaching group sessions
Description: Nutritional coaching group sessions held via zoom and performed by a certified clinical nutritionist regarding nutrition, and physical activity specific for weight loss.
Study: NCT05540067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavior Therapy (ABBT)
Description: In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-as-Usual (TAU)
Description: TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
Study: NCT06478628

Intervention type: BEHAVIORAL
Intervention: Outpatient day rehabilitation
Description: Multimodal rehabilitation in specialist health care with program lasting whole work days
Study: NCT05113303

Intervention type: DEVICE
Intervention: Navigated Revision Total Knee Arthroplasty
Description: Patients in the case group receive a Columbus® Revision knee prosthesis, implanted with computer assisted surgery

Intervention type: DEVICE
Intervention: Manual Revision Total Knee Arthroplasty
Description: Patients in the control group will correspond to a historical cohort of patients in which manual jig-assisted knee revision was done.
Study: NCT06488105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
Description: moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Counseling
Description: Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Counseling
Description: Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Followup
Description: Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Followup
Description: Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral
Study: NCT06569303

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Incredible Years® School Age Basic Parent Training Program
Description: The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
Study: NCT05869721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
Study: NCT06149429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized virtual reality experience
Description: The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset.
Study: NCT06552091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-hypnosis sessions
Description: 3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily
Study: NCT05888311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid bandage
Description: Liquid elastic collodion- and benzethonium chloride-based topical solution
Study: NCT06112626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHG Skin Treatment Video
Description: Short CHG skin treatment video that reviews the rationale/importance of CHG bathing, and the appropriate process for bathing